
    
      The study is an open label, multicenter phase IIa clinical trial which is designed as a pilot
      project in order to establish the efficacy and tolerability of Multiferon as a neoadjuvant
      treatment of locoregional metastases. Patients will be treated subsequently in cohorts
      characterized by different doses (3 - 9 - 18 MIU) to analyze dosage dependent effects.
    
  